AestheticsFeatured ArticlesPhotoprotectionSkin of Color

Impact of Iron-Oxide Containing Formulations Against Visible Light-Induced Skin Pigmentation in Skin of Color Individuals

By September 9, 2020September 14th, 2020No Comments

Featured Article

Featured Article

In this study, the efficacy of two formulations containing iron oxide was evaluated in preventing visible light-induced pigmentation compared with a non-tinted mineral SPF 50+ sunscreen.

Read more

In this study, the efficacy of two formulations containing iron oxide was evaluated in preventing visible light-induced pigmentation compared with a non-tinted mineral SPF 50+ sunscreen.

Hawasatu Dumbuya PhD, Pearl E Grimes MD, Stephen Lynch PhD, Kalli Ji PhD, Manisha Brahmachary PhD, Qian Zheng Md PhD, Charbel Bouez PhD, Janet Wangari-Talbot PhD

 

 

Visible light (400–700nm), which contributes to 45% of solar radiation, contributes to skin darkening and worsening of dyschromias, particularly in individuals with Fitzpatrick skin phototypes III and higher.

The pathogenesis of melasma is incompletely understood, which poses a challenge for disease management. Causative factors include genetics, ultraviolet (UV) radiation, cosmetics, pregnancy, hormonal therapy, phototoxic drugs, and various medications.

Currently, sunscreens provide limited protection against that spectrum. Due to their capabilities in absorbing, scattering, and reflecting visible light, topical products containing pigments and/or metal oxides can provide additional photoprotection.

In this study, the efficacy of two formulations containing iron oxide was evaluated in preventing visible light-induced pigmentation compared with a non-tinted mineral SPF 50+ sunscreen. Expert grading and colorimetry demonstrated that the iron-oxide containing formulations significantly protected against visible light-induced pigmentation compared to untreated skin or mineral SPF 50+ sunscreen in Fitzpatrick IV individuals.

Read Full Article Now
Article Cited in this Post

Open Access Articles

The Journal of Drugs in Dermatology (JDD) presents Open Access content, unrestricted access to our original articles, award-winning case studies, clinical trial reviews and clearance updates, drugs and devices, and special content geared toward medical residents and other allied health professionals.
Articles are reviewed by the Editorial Board of renowned experts, from key opinion leaders to well-known clinicians. View our open-access dermatology articles now.
View All Open Access Articles

You May Also Like

JDD in the News: Acne Information on Instagram, CAL/BDP Cream Improves QoL

| Featured Articles, JDD Highlights, JDD Higlights, JDD in the Media, The Latest | No Comments
By Allison Sit HCP Live covered a March JDD study in its article, “Acne-Related Social Media Content Lacking Dermatologist Input.” The study, “Acne Information on Instagram: Quality of Content and…

Novel Biome-Care Technology of C. acnes subsp. defendens Demonstrates Health and Aesthetic Benefits for Facial Skin

| Featured Articles, JDD Highlights, JDD Webinars, Rosacea, The Latest, Webinars on Demand | No Comments
As one ages, changes to skin biology can result in a shift in the skin biome causing microbial imbalance (dysbiosis) and significant reductions in certain microbial populations that maintain skin…

JDD in the News: AI Perceptions, Platelet Count & Psoriasis

| Featured Articles, JDD Highlights, JDD Higlights, JDD in the Media, The Latest | No Comments
By Allison Sit Dermatology News, Dermatology Times and Practical Dermatology all wrote about the February JDD study, “Perceptions of Artificial Intelligence Integration into Dermatology Clinical Practice: A Cross-Sectional Survey Study.”…

Leave a Reply